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Abstract
CRISPR RNA-guided endonucleases (RGENs) have rapidly emerged as a facile and efficient
platform for genome editing. Here, we use a human cell-based reporter assay to characterize off-
target cleavage of Cas9-based RGENs. We find that single and double mismatches are tolerated to
varying degrees depending on their position along the guide RNA (gRNA)-DNA interface. We
readily detected off-target alterations induced by four out of six RGENs targeted to endogenous
loci in human cells by examination of partially mismatched sites. The off-target sites we identified
harbor up to five mismatches and many are mutagenized with frequencies comparable to (or
higher than) those observed at the intended on-target site. Our work demonstrates that RGENs are
highly active even with imperfectly matched RNA-DNA interfaces in human cells, a finding that
might confound their use in research and therapeutic applications.
Recent work has demonstrated that clustered, regularly interspaced, short palindromic
repeats (CRISPR)/CRISPR-associated (Cas) systems1–3 can serve as the basis of a simple
and highly efficient method for performing genome editing in bacteria, yeast and human
cells, as well as in vivo in whole organisms such as fruit flies, zebrafish and mice4–13. The
Cas9 nuclease from S. pyogenes (hereafter simply Cas9) can be guided via simple base pair
complementarity between the first 20 nucleotides of an engineered gRNA and a target
genomic DNA sequence of interest that lies next to a protospacer adjacent motif (PAM)
matching the sequence NGG5–12, 14 (Supplementary Fig. 1). Previous studies performed in
vitro14, in bacteria7 and in human cells10 have shown that Cas9-mediated cleavage can be
abolished by single mismatches at the gRNA/target site interface, particularly in the last 10–
12 nucleotides located in the 3’ end of the 20 nt gRNA targeting region. Although Maraffini
and colleagues7 recently performed a systematic investigation of Cas9 RGEN specificity in
bacteria, the specificities of RGENs in human cells have not been extensively defined and,
to our knowledge, bona fide off-target mutations induced by Cas9 have not been identified
in any eukaryotic cell or organism. Understanding the scope of RGEN-mediated off-target
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teffects in human and other eukaryotic cells will be critically essential if these nucleases are
to be used widely for research and therapeutic applications.
To begin to define the specificity determinants of RGENs in human cells, we sought to
perform a large-scale test in which we assessed the effects of systematically mismatching
various positions within multiple gRNA/target DNA interfaces. To do this, we used a
quantitative human cell-based enhanced green fluorescent protein (EGFP) disruption assay
previously described by our lab15 that enables rapid quantitation of targeted nuclease
activities (Fig. 1a). In this assay, the activities of nucleases targeted to a single integrated
EGFP reporter gene can be quantified by assessing loss of fluorescence signal in human
U2OS.EGFP cells caused by inactivating frameshift insertion/deletion (indel) mutations
introduced by error prone non-homologous end-joining (NHEJ) repair of nuclease-induced
double-stranded breaks (DSBs) (Fig. 1a and Methods). For the studies described here, we
used three ~100 nt single gRNAs (sgRNAs) targeted to different sequences within EGFP
(Supplementary Fig. 2); each of these sgRNAs can efficiently direct Cas9-mediated
disruption of EGFP expression (Supplementary Results).
In initial experiments, we tested the effects of single nucleotide mismatches at 19 of 20
nucleotides in the complementary targeting region of our three EGFP-targeted sgRNAs. To
do this, we generated variant sgRNAs for each of the three target sites harboring Watson-
Crick transversion mismatches at positions 1 through 19 (numbered 1 to 20 in the 3’ to 5’
direction; see Supplementary Fig. 1) and tested the abilities of these various sgRNAs to
direct Cas9-mediated EGFP disruption in human cells. (We did not generate variant sgRNAs
bearing a substitution at position 20 because this nucleotide is part of the U6 promoter
sequence and therefore must remain a guanine to avoid affecting expression.) For EGFP
target site #2, single mismatches in positions 1 – 10 of the sgRNA have dramatic effects on
associated Cas9 activity (Fig. 1b, middle panel), consistent with previous studies that
suggest mismatches at the 5’ end of gRNAs are better tolerated than those at the 3’
end7, 10, 14. However, we found with EGFP target sites #1 and #3 that single mismatches at
all but a few positions in the sgRNA appear to be well tolerated, even within the 3’ end of
the sequence. Furthermore, the specific positions that are sensitive to mismatch differ for
these two targets (Fig. 1b, compare top and bottom panels) – for example, target site #1 is
particularly sensitive to a mismatch at position 2 whereas target site #3 is most sensitive to
mismatches at positions 1 and 8.
To test the effects of more than one mismatch at the sgRNA/DNA interface, we created a
series of variant sgRNAs bearing double Watson-Crick transversion mismatches in adjacent
(Fig. 1c) and separated (Fig. 1d) positions and tested the abilities of these to direct Cas9
nuclease activity in human cells using our EGFP disruption assay. All three target sites
generally showed greater sensitivity to double alterations in which one or both mismatches
occur within the 3’ half of the sgRNA targeting region (Figs. 1c and 1d). However, the
magnitude of these effects exhibited site-specific variation, with target site #2 showing the
greatest sensitivity to these double mismatches and target site #1 generally showing the least
(Figs. 1c and 1d). To test the number of adjacent mismatches that can be tolerated, we
constructed variant sgRNAs bearing increasing numbers of mismatched positions ranging
from positions 19 to 15 in the 5’ end of the sgRNA targeting region (where single and
double mismatches appear to be better tolerated) (Fig. 1e). Testing of these increasingly
mismatched sgRNAs revealed that for all three target sites, the introduction of three or more
adjacent mismatches results in significant loss of RGEN activity (Fig. 1e). Taken together,
our results in human cells confirm that the activities of RGENs can be more sensitive to
mismatches in the 3’ half of the sgRNA targeting sequence. However, our data also clearly
reveal that the specificity of RGENs is complex and target site-dependent, with single and
double mismatches often well tolerated even when one or more mismatches occur in the 3’
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thalf of the sgRNA targeting region. Furthermore, our data also suggest that not all
mismatches in the 5’ half of the sgRNA/DNA interface are necessarily well tolerated.
We next sought to determine whether we could identify off-target mutations for RGENs
targeted to endogenous human genes. To accomplish this, we used six sgRNAs that target
three different sites in the VEGFA gene, one in the EMX1 gene, one in the RNF2 gene, and
one in the FANCF gene (Table 1 and Supplementary Table 1). These six sgRNAs
efficiently directed Cas9-mediated indels at their respective endogenous loci in human
U2OS.EGFP cells as detected by T7 Endonuclease I (T7EI) assay (Online Methods and
Table 1). For each of these six RGENs, we then examined dozens of potential off-target sites
(ranging in number from 46 to as many as 64) for evidence of nuclease-induced NHEJ-
mediated indel mutations in U2OS.EGFP cells. The loci we assessed included all genomic
sites that differ by one or two nucleotides as well as subsets of genomic sites that differ by
three to six nucleotides and with a bias toward those that had one or more of these
mismatches in the 5’ half of the sgRNA targeting sequence (Supplementary Table 2). Using
the T7EI assay, we readily identified four off-target sites (out of 53 candidate sites
examined) for VEGFA site 1, twelve (out of 46 examined) for VEGFA site 2, seven (out of
64 examined) for VEGFA site 3 and one (out of 46 examined) for the EMX1 site (Table 1
and Supplementary Table 2). No off-target mutations were detected among the 43 and 50
potential sites examined for the RNF2 or FANCF genes, respectively (Supplementary Table
2). The rates of mutation at verified off-target sites were very high, ranging from 5.6% to
125% (mean of 40%) of the rate observed at the intended target site (Table 1). These bona
fide off-targets included sequences with mismatches in the 3’ end of the target site and with
as many as a total of five mismatches, with most off-target sites occurring within protein
coding genes (Table 1). DNA sequencing of a subset of off-target sites provided additional
molecular confirmation that indel mutations occur at the expected RGEN cleavage site
(Supplementary Fig. 3).
Having established that RGENs can induce off-target mutations with high frequencies in
U2OS.EGFP cells, we next sought to determine whether these nucleases would also have
these effects in other types of human cells. We had chosen U2OS.EGFP cells for our initial
experiments because we previously used these cells to evaluate the activities of TALENs15
but human HEK293 and K562 cells have been more widely used to test the activities of
targeted nucleases. Therefore, we also assessed the activities of the four RGENs targeted to
VEGFA sites 1, 2, and 3 and the EMX1 site in HEK293 and K562 cells. We found that each
of these four RGENs efficiently induced NHEJ-mediated indel mutations at their intended
on-target site in these two additional human cell lines (as assessed by T7EI assay) (Table 1),
albeit with somewhat lower mutation frequencies than those observed in U2OS.EGFP cells.
Assessment of the 24 off-target sites for these four RGENs originally identified in
U2OS.EGFP cells revealed that many were again mutated in HEK293 and K562 cells with
frequencies similar to those at their corresponding on-target site (Table 1). As expected,
DNA sequencing of a subset of these off-target sites from HEK293 cells provided additional
molecular evidence that alterations are occurring at the expected genomic loci
(Supplementary Figure 4). We do not know for certain why in HEK293 cells four and in
K562 cells eleven of the off-target sites identified in U2OS.EGFP cells did not show
detectable mutations. However, we note that many of these off-target sites also showed
relatively lower mutation frequencies in U2OS.EGFP cells. Therefore, we speculate that
mutation rates of these sites in HEK293 and K562 cells may be falling below the reliable
detection limit of our T7EI assay (~2–5%) because RGENs generally appear to have lower
activities in HEK293 and K562 cells compared with U2OS.EGFP cells in our experiments.
Taken together, our results in HEK293 and K562 cells provide evidence that the high-
frequency off-target mutations we observe with RGENs will be a general phenomenon seen
in multiple human cell types.
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nor straightforward. Our EGFP reporter assay experiments show that single and double
mismatches can have variable effects on RGEN activity in human cells that do not strictly
depend upon their position(s) within the target site. For example, consistent with previously
published reports, alterations in the 3’ half of the sgRNA/DNA interface generally have
greater effects than those in the 5’ half7, 10, 14; however, single and double mutations in the
3’ end sometimes also appear to be well tolerated whereas double mutations in the 5’ end
can greatly diminish activities. In addition, the magnitude of these effects for mismatches at
any given position(s) appears to be site-dependent. Comprehensive profiling of a large series
of RGENs with testing of all possible nucleotide substitutions (beyond the Watson-Crick
transversions used in our EGFP reporter experiments) may help provide additional insights
into the range of potential off-targets. In this regard, the recently described bacterial cell-
based method of Maraffini and colleagues7 or the in vitro, combinatorial library-based
cleavage site-selection methodologies previously applied to ZFNs by Liu and colleagues16
might be useful for generating larger sets of RGEN specificity profiles.
Despite these challenges in comprehensively predicting RGEN specificities, we were able to
identify bona fide off-targets of RGENs with relative ease simply by examining a subset of
genomic sites that differed from the on-target site by one to five mismatches. Notably, under
conditions of our experiments, the frequencies of RGEN-induced mutations at many of these
off-target sites were similar to (or higher than) those observed at the intended on-target site,
enabling us to identify them using the simple and relatively insensitive T7EI assay (which,
as performed in our laboratory, has a reliable detection limit of ~2 to 5% mutation
frequency). Because these mutation rates were very high, we were able to avoid using deep
sequencing methods previously required to detect much lower frequency ZFN- and TALEN-
induced off-target alterations16–19. Our analysis of RGEN off-target mutagenesis in human
cells also confirmed the difficulties of predicting RGEN specificities – not all single and
double mismatched off-target sites show evidence of mutation whereas some sites with as
many as five mismatches can also show alterations. Furthermore, the bona fide off-target
sites we identified do not exhibit any obvious bias toward transition or transversion
differences relative to the intended target sequence (Supplementary Table 2; grey
highlighted rows).
Although we have unveiled off-target sites for a number of RGENs, we note that our
identification of these sites was neither comprehensive nor genome-wide in scale. For the
six RGENs we studied, we only examined a very small subset of the much larger total
number of potential off-target sequences in the human genome (sites that differ by three to
six nucleotides from the intended target site; compare Supplementary Tables 2 and 3).
Although examining such large numbers of loci for off-target mutations by T7EI assay is
neither a practical nor a cost-effective strategy, the use of high-throughput sequencing in
future studies might enable the interrogation of larger numbers of candidate off-target sites
and provide a more sensitive method for detecting bona fide off-target mutations. For
example, such an approach might enable the unveiling of additional off-target sites for the
two RGENs for which we failed to uncover any off-target mutations. In addition, an
improved understanding both of RGEN specificities and of any epigenomic factors (e.g.--
DNA methylation and chromatin status) that may influence RGEN activities in cells might
also reduce the number of potential sites that need to be examined and thereby make
genome-wide assessments of RGEN off-targets more practical and affordable.
It will be interesting to investigate whether the specific choice of RGEN target site can be
used to minimize the frequencies of genomic off-target mutations. Given that off-target sites
that differ at up to five positions from the intended target site can be efficiently mutated by
RGENs, attempting to choose target sites with minimal numbers of off-target sites as judged
Fu et al. Page 4
Nat Biotechnol. Author manuscript; available in PMC 2014 March 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tby simple mismatch counting seems unlikely to be effective; thousands of potential off-
target sites that differ by four or five positions within the 20 bp RNA:DNA complementarity
region will typically exist for any given RGEN targeted to a sequence in the human genome
(see, for example, Supplementary Table 3). It is also possible that the nucleotide content of
the gRNA complementarity region might influence the range of potential off-target effects.
For example, high GC-content has been shown to stabilize RNA:DNA hybrids20 and
therefore might also be expected to make gRNA/genomic DNA hybridization more stable
and more tolerant to mismatches. Additional experiments with larger numbers of gRNAs
will be needed to assess if and how these two parameters (numbers of mismatched sites in
the genome and stability of the RNA:DNA hybrid) influence the genome-wide specificities
of RGENs. However, it is important to note that even if such predictive parameters can be
defined, the effect of implementing such guidelines would be to further restrict the targeting
range of RGENs.
Another potential general strategy for reducing RGEN-induced off-target effects might be to
reduce the concentrations of gRNA and Cas9 nuclease expressed in the cell. We tested this
idea using the RGENs for VEGFA target sites 2 and 3 in U2OS.EGFP cells but found that
transfecting less sgRNA- and Cas9-expressing plasmid decreased the mutation rate at the
on-target site but did not appreciably change the relative rates of off-target mutations (Table
2 and Supplementary Table 4). Consistent with this, we note that we also observe high-level
off-target mutagenesis in two other human cell types (HEK293 and K562 cells) even though
the absolute rates of on-target mutagenesis are lower than in U2OS.EGFP cells. Although
additional work is clearly needed to further explore this strategy, these initial experiments
suggest that reducing expression levels of gRNA and Cas9 in cells is not likely to provide a
simple solution for reducing off-target effects. Furthermore, these results also suggest that
the high rates of off-target mutagenesis we observe in human cells are not caused by
overexpression of sgRNA and/or Cas9.
Our finding that significant off-target mutagenesis can be induced by RGENs in three
different human cell types has important implications for broader use of this genome-editing
platform. For research applications, the potentially confounding effects of high frequency
off-target mutations will need to be considered, particularly for experiments involving either
cultured cells or organisms with slow generation times for which the outcrossing of
undesired alterations would be challenging. One way to control for such effects might be to
utilize multiple RGENs targeted to different DNA sequences to induce the same genomic
alteration as off-target effects are not random but instead related to the targeted site.
However, for therapeutic applications, our findings clearly indicate that the specificities of
RGENs will need to be carefully defined and/or improved if these nucleases are to be used
safely in the longer term for treatment of human diseases.
Online Methods
Construction of guide RNAs
DNA oligonucleotides (Supplementary Table 1) harboring variable 20 nt sequences for Cas9
targeting were annealed to generate short double-strand DNA fragments with 4 bp
overhangs compatible with ligation into BsmBI-digested plasmid pMLM3636. Cloning of
these annealed oligonucleotides generates plasmids encoding a chimeric +103 single-chain
guide RNA with 20 variable 5’ nucleotides under expression of a U6 promoter9, 11.
pMLM3636 and the expression plasmid pJDS246 (encoding a codon optimized version of
Cas9) used in this study are both available through the non-profit plasmid distribution
service Addgene (http://www.addgene.org/crispr-cas).
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tEGFP Activity Assays
U2OS.EGFP cells harboring a single integrated copy of an EGFP-PEST fusion gene were
cultured as previously described15. For transfections, 200,000 cells were Nucleofected with
the indicated amounts of sgRNA expression plasmid and pJDS246 together with 30 ng of a
Td-tomato-encoding plasmid using the SE Cell Line 4D-Nucleofector™ X Kit (Lonza)
according to the manufacturer’s protocol. Cells were analyzed 2 days post-transfection using
a BD LSRII flow cytometer. Transfections for optimizing gRNA/Cas9 plasmid
concentration were performed in triplicate and all other transfections were performed in
duplicate.
PCR amplification and sequence verification of endogenous human genomic sites
PCR reactions were performed using Phusion Hot Start II high-fidelity DNA polymerase
(NEB) with PCR primers and conditions listed in Supplementary Table 2. Most loci
amplified successfully using touchdown PCR (98 °C, 10 s; 72–62 °C, −1 °C/cycle, 15 s; 72
°C, 30 s]10 cycles, [98 °C, 10 s; 62 °C, 15 s; 72 °C, 30 s]25 cycles). PCR for the remaining
targets were performed with 35 cycles at a constant annealing temperature of 68 °C or 72 °C
and 3% DMSO or 1M betaine, if necessary. PCR products were analyzed on a QIAXCEL
capillary electrophoresis system to verify both size and purity. Validated products were
treated with ExoSap-IT (Affymetrix) and sequenced by the Sanger method (MGH DNA
Sequencing Core) to verify each target site.
Determination of RGEN-induced on- and off-target mutation frequencies in human cells
For U2OS.EGFP and K562 cells, 2 × 105 cells were transfected with 250 ng of sgRNA
expression plasmid or an empty U6 promoter plasmid (for negative controls), 750 ng of
Cas9 expression plasmid, and 30 ng of td-Tomato expression plasmid using the 4D
Nucleofector System according to the manufacturer’s instructions (Lonza). For HEK293
cells, 1.65 × 105 cells were transfected with 125 ng of sgRNA expression plasmid or an
empty U6 promoter plasmid (for the negative control), 375 ng of Cas9 expression plasmid,
and 30 ng of a td-Tomato expression plasmid using Lipofectamine LTX reagent according
to the manufacturer’s instructions (Life Technologies). Genomic DNA was harvested from
transfected U2OS.EGFP, HEK293, or K562 cells using the QIAamp DNA Blood Mini Kit
(QIAGEN), according to the manufacturer’s instructions. To generate enough genomic
DNA to amplify the off-target candidate sites, DNA from three Nucleofections (for
U2OS.EGFP cells), two Nucleofections (for K562 cells), or two Lipofectamine LTX
transfections was pooled together before performing T7EI. This was done twice for each
condition tested, thereby generating duplicate pools of genomic DNA representing a total of
four or six individual transfections. PCR was then performed using these genomic DNAs as
templates as described above and purified using Ampure XP beads (Agencourt) according to
the manufacturer’s instructions. T7EI assays were performed as previously described15.
DNA sequencing of NHEJ-mediated indel mutations
Purified PCR products used for the T7EI assay were cloned into Zero Blunt TOPO vector
(Life Technologies) and plasmid DNAs were isolated using an alkaline lysis miniprep
method by the MGH DNA Automation Core. Plasmids were sequenced using an M13
forward primer (5’ – GTAAAACGACGGCCAG – 3’) by the Sanger method (MGH DNA
Sequencing Core).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFig. 1. Activities of RGENs harboring variant mismatched sgRNAs in a human cell-based EGFP
disruption assay
(a) Schematic overview of the EGFP disruption assay. Repair of targeted Cas9-mediated
double-stranded breaks in a single integrated EGFP-PEST reporter gene by error-prone
NHEJ-mediated repair leads to frameshift mutations that disrupt the coding sequence and to
associated loss of fluorescence in cells. Activities of RGENs harboring sgRNAs bearing (b)
single mismatches, (c) adjacent double mismatches, (d) variably spaced double mismatches,
and (e) increasing numbers of adjacent mismatches assayed on three different target sites in
the EGFP reporter gene sequence. Mean activities of replicates (see Online Methods) are
shown, normalized to the activity of a perfectly matched sgRNA. Error bars indicate
standard errors of the mean. Positions mismatched in each sgRNA are highlighted in grey in
the grid below. Sequences of the three EGFP target sites are shown in Supplementary Figure
2a.
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Table 2
Indel mutation frequencies at on- and off-target genomic sites induced by different
amounts of Cas9- and sgRNA-expressing plasmids for the RGEN targeted to VEGFA
Target Site 2
Amounts of sgRNA- and Cas9-expressing plasmids transfected into U2OS.EGFP cells for these assays are
shown at the top of each column. (Note that data for 250 ng sgRNA/750 ng Cas9 are the same as those
presented in Table 1.) Mean indel frequencies were determined using the T7EI assay from replicate samples as
described in Online Methods.
Site Sequence 250ng sgRNA/750 ng
Cas9
Mean indel frequency
(%) ± SEM
12.5ng sgRNA/50 ng
Cas9
Mean indel frequency
(%) ± SEM
T2 (On-target) GACCCCCTCCACCCCGCCTCCGG 50.2 ± 4.9 25.4 ± 4.8
OT2-1 GACCCCCCCCACCCCGCCCCCGG 14.4 ±3.4 4.2 ± 0.2
OT2-2 GGGCCCCTCCACCCCGCCTCTGG 20.0 ± 6.2 9.8 ± 1.1
OT2-6 CTACCCCTCCACCCCGCCTCCGG 8.2 ± 1.4 6.0 ± 0.5
OT2-9 GCCCCCACCCACCCCGCCTCTGG 50.7 ± 5.6 16.4 ± 2.1
OT2-15 TACCCCCCACACCCCGCCTCTGG 9.7 ± 4.5 2.1 ± 0.0
OT2-17 ACACCCCCCCACCCCGCCTCAGG 14.0 ± 2.8 7.1 ± 0.0
OT2-19 ATTCCCCCCCACCCCGCCTCAGG 17.0 ± 3.3 9.2 ± 0.4
OT2-20 CCCCACCCCCACCCCGCCTCAGG 6.1 ± 1.3 N.D.
OT2-23 CGCCCTCCCCACCCCGCCTCCGG 44.4 ± 6.7 35.1 ± 1.8
OT2-24 CTCCCCACCCACCCCGCCTCAGG 62.8 ± 5.0 44.1 ± 4.5
OT2-29 TGCCCCTCCCACCCCGCCTCTGG 13.8 ± 5.2 5.0 ± 0.2
OT2-34 AGGCCCCCACACCCCGCCTCAGG 2.8 ± 1.5 N.D.
OT = Off-target sites, numbered as in Table 1 and Supplementary Table 2. Mismatches from the on-target site (within the 20 bp region to which
the gRNA hybridizes) are highlighted as bold, underlined text. N.D. = none detected
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